학술논문
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial
Document Type
Article
Author
Gebhart, G.; Guiot, T.; Flamen, P.; Keyaerts, M.; Ruiz-Borrego, M.; Stradella, A.; Bermejo, B.; Escriva-De-Romani, S.; Martínez, L.C.; Ribelles, N.; Fernandez-Abad, M.; Albacar, C.; Colleoni, M.; Garrigos, L.; de Frutos, M.A.; Cortés, J.; Dalenc, F.; Prat, A.; Marmé, F.; Schmid, P.; Kerrou, K.; Braga, S.; Gener, P.; Sampayo-Cordero, M.; Pérez-García, J.M.; Llombart-Cussac, A.
Source
In: Journal of Nuclear Medicine . (Journal of Nuclear Medicine, 2024, 65(5):708-713)
Subject
Language
English
ISSN
2159662X
01615505
01615505